AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
Almirall signs atopic dermatitis R&D deal with HitgenAlmirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for Share XAlmirall signs atopic dermatitis R&D deal with Hitgenhttps://pharmaphorum.com/news/almirall-signs-atopic-dermatitis-rd-deal-with-hitgen/
Lilly scores with two Olumiant trials in atopic dermatitisEli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which Share XLilly scores with two Olumiant trials in atopic dermatitishttps://pharmaphorum.com/news/lilly-scores-with-two-olumiant-trials-in-atopic-dermatitis/
Biotech strategy and nanomedicine: the pharmaphorum podcastFor episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Share XBiotech strategy and nanomedicine: the pharmaphorum podcasthttps://pharmaphorum.com/r-d/biotech-strategy-and-nanomedicine/
J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasisA large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had Share XJ&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasishttps://pharmaphorum.com/news/jjs-tremfya-outperforms-novartis-cosentyx-in-psoriasis/
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasisNICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but Share XNICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasishttps://pharmaphorum.com/news/nice-okays-ucbs-cimzia-nixes-almirall-ilumetri-in-psoriasis/
NICE okays funding for Novartis skin cancer comboThe combination of the Novartis drugs dabrafenib and trametinib for patients with stage 3 skin cancer will be Share XNICE okays funding for Novartis skin cancer combohttps://pharmaphorum.com/news/nice-okays-funding-for-novartis-skin-cancer-combo/
Sanofi to continue with cost-cutting as new drugs show promiseSanofi is to push on with cost-cutting after reaching a target of 1.5 billion euros a year ahead Share XSanofi to continue with cost-cutting as new drugs show promisehttps://pharmaphorum.com/news/sanofi-to-continue-with-cost-cutting-as-new-drugs-show-promise/
Sanofi unveils eczema drug data, as regulators mull label expansionSanofi has revealed details of research, which forms the basis of filings to extend the use of its eczema Share XSanofi unveils eczema drug data, as regulators mull label expansionhttps://pharmaphorum.com/news/sanofi-unveils-eczema-drug-data-as-regulators-mull-label-expansion/
